“Demiurge is responding to the outbreak of the 2019 novel coronavirus (COVID-19) through the appropriate use of our AI platform of discovering novel therapeutic solutions and predicting clinical trial outcomes. We are conducting deep analyses of published studies and clinical data on COVID-19 against our precise broad-spectrum virology models.
In addition to the previous discoveries of multiple PI3K inhibitors as novel therapeutic options for COVID-19, we hereby officially announce further discoveries of the clinical benefits and risks of Remdesivir, Chloroquine, and PI3K inhibitors against COVID-19: […]”
Read the full article @ Demiurge Technologies:
Demiurge AI Discovers the Clinical Benefits and Risks of Remdesivir, Chloroquine, and PI3K inhibitors against 2019 Novel Coronavirus (COVID-19)
SWITZERLAND, SUNDAY, 23 FEBRUARY 2020 7:35 AM CET Demiurge is responding to the outbreak of the 2019 novel coronavirus (COVID-19) through the appropriate use of our AI platform of